# Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT02152982** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 447 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Temozolomide
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT02152982
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12-15
- **Primary completion:** 2021-12-01
- **Final completion:** 2026-12-26
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152982, "Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02152982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*